MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Asymmetric synaptic density and glucose consumption in subjects with non-demented Parkinson’s Disease, as measured with [11C]UCB-J and [18F]FDG PET.

    K. Andersen, A. Hansen, J. Horsager, K. Knudsen, P. Borghammer (Aarhus, Denmark)

    Objective: The objective of this study was to investigate asymmetric synaptic density and glucose consumption in moderate-stage non demented PD patients and the association between…
  • 2023 International Congress

    Improvement of nocturia symptoms and associated quality of life in patients with Parkinson’s disease treated with foslevodopa/foscarbidopa: results from 2 phase 3 trials

    K. Chaudhuri, M. Bouchard, E. Freire-Alvarez, R. Pahwa, L. Bergmann, R. Gupta, P. Kukreja, M. Shah, S. Isaacson (London, United Kingdom)

    Objective: To assess nocturia over time and its correlation with quality of life (QoL) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDP/CDP). Background:…
  • 2023 International Congress

    Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study

    W. Poewe, A. Ellenbogen, F. Stocchi, L. Adar, L. Salin, R. Case, T. Yardeni, N. Giladi (Innsbruck, Austria)

    Objective: To evaluate three-year outcomes from the ND0612 BeyoND study. Background: Investigational ND0612 is in development as a 24-hour continuous, subcutaneous infusion of liquid levodopa/carbidopa…
  • 2023 International Congress

    Motor evaluation of Parkinson disease and Vascular parkinsonism using the TUG encephalog application

    L. Franken, J. Reiner, M. Mermelstein, D. Biederko, R. Djaldettti (Petah Tikva, Israel)

    Objective: We aimed to compare gait and parkinsonian features between PD patients, VP patients and PD patients with Vascular component (PDVC) using a smartphone-based motion…
  • 2023 International Congress

    REM sleep behaviour disorder in Parkinson’s disease: prevalence and correlation with other sleep parameters

    S. Diaconu, L. Ungureanu, A. Zarnoveanu, B. Ciopleias, V. Vasile, A. Iacob, T. Moldovan, C. Falup-Pecurariu (Brasov, Romania)

    Objective: to assess the prevalence of probable rapid eye movement (REM) sleep behavior disorder (RBD) in Parkinson’s disease (PD) patients and its correlation with other…
  • 2023 International Congress

    Vagus nerve degeneration in Parkinson’s disease: correlation with autonomic symptoms and pupillography

    M. Batchakaschvili, M. Löhle, HR. Kleinlein, W. Hermann, H. Walter, A. Storch, U. Walter (Rostock, Germany)

    Objective: To test the hypothesis that vagus nerve (VN) atrophy is pronounced in the body-first subtype of Parkinson’s disease (PD) and coincides with pupillary dysfunction.…
  • 2023 International Congress

    Filipino’s and Parkinson’s Disease: A Scoping Review of the Literature

    E. Krening, T. Seto, M. Bruno (Honolulu, USA)

    Objective: To review the literature on Parkinson’s disease (PD) in Filipino’s and identify specific studies focusing on Filipino-Americans and Parkinson’s disease. Background: Filipino’s are the…
  • 2023 International Congress

    Online recruitment and retention in the Parkinson’s Progression Markers Initiative (PPMI)

    C. Tanner, E. Brown, L. Chahine, D. Weintraub, R. Dobkin, W. Poewe, E. Tolosa, C. Marras, S. Schade, C. Coffey, M. Korell, C. Stanley, J. Valdeverde Twiggs, M. Kuhl, K. Fabrizio, S. Chowdhury, T. Sherer, A. Siderowf, T. Simuni, K. Marek (SAN FRANCISCO, USA)

    Objective: To describe participants and retention in the longitudinal PPMI Online cohort Background: The overall PPMI aim of biomarker identification to enable therapeutic development is…
  • 2023 International Congress

    MR-guided focused ultrasound pallidothalamic tractotomy in non-tremor dominant (akinetic-rigid) Parkinson’s disease treatment

    R. Galimova, G. Akhmadeeva, D. Nabiullina, F. Kashapov, O. Kachemaeva, YU. Sidorova, D. Teregulova, N. Mukhamadeeva, D. Krekotin, I. Buzaev, SH. Safin, S. Illarioshkin (Ufa, Russian Federation)

    Objective: The study aims to show that unilateral MR-guided focused ultrasound (MRgFUS) treatment akinetic-rigid Parkinson's disease (PD) can be safe and effective. Background: Parkinson's disease…
  • 2023 International Congress

    From the Healthy Brain Ageing (HeBA) Cohort: Frequency of key risk factors for Parkinson in a European Cohort

    A. Garrido, C. Horlings, C. Vega, S. Schade, S. Ghosh, K. Rege, R. Rawal, T. Marques, P. Mahlknecht, C. Gomes, C. Pauly, D. Mcintyre, K. Seppi, MJ. Martí, C. Trenkwalder, E. Tolosa, W. Poewe, V. Satagopam, R. Krüger, B. Mollenhauer (Barcelona, Spain)

    Objective: To present the baseline data on common risk factors for Parkinson’s disease (PD) in the population-based cohort of the HeBA study (Ref Poster 1)…
  • « Previous Page
  • 1
  • …
  • 245
  • 246
  • 247
  • 248
  • 249
  • …
  • 436
  • Next Page »
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley